Wednesday, June 8, 2016

ValiRx (LON:VAL) in talks over cancer drug collaborations, says chief: ProactiveInvestors Stocktube

Published on 8 Jun 2016
Satu Vainikka, chief executive of ValiRx Plc (LON:VAL), tells Proactive Investors the company is discussions with larger companies over potential licencing deals and collaborations for its lead cancer drug VAL 201.

The company is to broaden the phase I/II clinical trial of its lead cancer drug to speed up the dose expansion stage, allowing it to complete the prostate cancer trial within the projected and regulatory-agreed time frame.
“A biotech business model is to take things from A to B and once you start reaching B, which in our case is Phase II clinical trials, we are starting to talk to big pharmaceutical companies or bigger biotech companies,” Vainikka says.

The company has also started preparatory work on a full efficacy study (phase III) of the drug in prostate cancer treatment.

No comments: